白藜芦醇作为控制良好2型糖尿病患者的附加治疗:一项随机对照试验
17例控制良好的2型糖尿病患者以随机双盲交叉设计接受安慰剂与150 mg/天白藜芦醇(resVida)各30天,主要终点为高胰岛素-正血糖钳夹测定的胰岛素敏感性。白藜芦醇未影响肝脏或外周胰岛素敏感性,肝脏内脂质含量亦未受影响,但肝脏内脂质含量变化与血浆白藜芦醇水平呈负相关(R = -0.68,P = 0.03)。
要点
- 白藜芦醇150 mg/天30天未改善控制良好2型糖尿病患者的肝脏或外周胰岛素敏感性。
- 白藜芦醇治疗使2型肌纤维内肌细胞内脂质含量增加(P = 0.03),收缩压呈下降趋势(P = 0.09)。
- 白藜芦醇显著改善离体线粒体功能(苹果酸加辛酰肉碱时state 3与state U呼吸,P < 0.005)。
核心结论
- 白藜芦醇补充不改善肝脏或外周胰岛素敏感性;结果质疑白藜芦醇作为2型糖尿病附加治疗的普遍价值,并强调需在未用药的2型糖尿病患者或糖尿病前期人群中开展研究。
研究设计与样本
- 随机双盲交叉研究,17例控制良好的2型糖尿病患者接受安慰剂与150 mg/天白藜芦醇(resVida)各30天。
- 主要结局指标为高胰岛素-正血糖钳夹技术测定的胰岛素敏感性。
主要发现
- 肝脏和外周胰岛素敏感性未受白藜芦醇治疗影响。
- 肝脏内脂质含量亦未受白藜芦醇影响,但肝脏内脂质含量变化与血浆白藜芦醇水平呈负相关(R = -0.68,P = 0.03)。
- 2型肌纤维内肌细胞内脂质含量增加(P = 0.03),收缩压在白藜芦醇治疗下呈下降趋势(P = 0.09)。
- 白藜芦醇显著改善离体线粒体功能(苹果酸加辛酰肉碱时state 3与state U呼吸,P < 0.005)。
- 白藜芦醇代谢物二氢白藜芦醇的血浆水平与患者所用二甲双胍剂量相关(R = 0.66,P = 0.005),提示二甲双胍与白藜芦醇之间存在相互作用。
临床怎么用
- 作者认为,白藜芦醇诱导的胰岛素增敏效应缺失可能由二甲双胍与白藜芦醇之间的相互作用所致。
- 作者强调需在未用药的2型糖尿病患者或糖尿病前期人群中开展研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether resveratrol supplementation can improve insulin sensitivity and promote overall metabolic health on top of standard diabetes care. RESEARCH DESIGN AND METHODS: Seventeen subjects with well-controlled type 2 diabetes (T2D) were treated with placebo and 150 mg/day resveratrol (resVida) in a randomized double-blind crossover study for 30 days. The main outcome measure was insulin sensitivity by the hyperinsulinemic-euglycemic clamp technique. RESULTS: Hepatic and peripheral insulin sensitivity were not affected by resveratrol treatment. Intrahepatic lipid content also remained unaffected by resveratrol; however, the change in intrahepatic lipid content correlated negatively with plasma resveratrol levels (R = -0.68, P = 0.03). Intramyocellular lipid content increased in type 2 muscle fibers (P = 0.03), and systolic blood pressure tended to decrease (P = 0.09) upon resveratrol treatment. In addition, resveratrol significantly improved ex vivo mitochondrial function (state 3 and state U respiration upon malate with octanoyl-carnitine, P < 0.005). Intriguingly, a correlation was found between plasma levels of a metabolite of resveratrol (dihydroresveratrol) and the metformin dose used by the patients (R = 0.66, P = 0.005), suggesting an interaction between metformin and resveratrol. It could be speculated that the lack of a resveratrol-induced insulin-sensitizing effect is caused by this interaction. CONCLUSIONS: Resveratrol supplementation does not improve hepatic or peripheral insulin sensitivity. Our results question the generalized value of resveratrol as an add-on therapy in the treatment of T2D and emphasize the need to perform studies in drug-naive patients with T2D or subjects with prediabetes.
引用
- Timmers S, de Ligt M, Phielix E, et al. Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2016. PMID: 27852684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。